Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Traveling Alone: An Excursion of Self-Disclosure - 2Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- 3Gen Z workplace stereotypes were TV’s favorite punchline in 2025
- 4Report in relation to renaming Herzog Park set to be withdrawn
- 5Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- A Manual for the Right SUV for Seniors
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Winter virus season so far is not too bad, but doctors worry about suffering to come
- I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
- Monetary Security: Building Serious areas of strength for an Establishment
- Cyber Monday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- Lilly, Novo lock horns in India's obesity drug race
- The most effective method to Safeguard Your Teeth from Acidic Food varieties and Beverages
- Best Disney Palace: Which One Catches Your Creative mind?
